Check the Lot Number: Canada Recalls Two Methotrexate Tablet Batches
Latest news on WhatsApp أجدد الأخبار على واتساب
JAMP Pharma has recalled two lots of its 10 mg methotrexate tablets from Canadian retailers because some packages may contain tablets that are larger than approved specifications.
Health Canada said the recall applies only to lot numbers 25JME01 and 25JME02, carrying Drug Identification Number DIN 02553740. The notice was published on August 5, 2026, after the recall began on July 30.
The agency classified the action as a Type II recall. This classification applies when exposure may cause temporary health consequences or when the likelihood of serious consequences is considered remote. The notice did not specify how much larger the tablets may be or how many packages were affected.
Methotrexate is a prescription medication used to treat certain cancers and, at lower doses, severe conditions including rheumatoid arthritis and psoriasis. Dosage and scheduling vary according to the condition, making it important not to change or stop treatment without professional advice.
Health Canada advised patients to check the lot number on their medication and consult a doctor or pharmacist before discontinuing the affected product. Consumers may also contact the company about the recall and report side effects or safety complaints to the department.
In practical terms, the recall does not cover every methotrexate product or every JAMP Pharma tablet. Patients whose packages carry either affected lot number should seek instructions from their pharmacist or healthcare provider rather than stopping treatment or discarding the medication themselves.
